RecruitingNCT05854927

Impact of the Spatial Resolution of Several Contrast-enhanced 3D T1-WI Sequences When Diagnosing Giant Cell Arteritis (GCA)

Sponsor

Fondation Ophtalmologique Adolphe de Rothschild

Enrollment

133 participants

Start Date

Jan 10, 2024

Study Type

OBSERVATIONAL

Conditions

Giant Cell Arteritis

Summary

Giant cell arteritis (GCA) (or Horton's disease) is a segmental and focal inflammatory arteritis affecting large and medium-sized arteries. Its incidence is estimated at 17.8/100,000 in subjects over 50 years old (and 46/100,000 in subjects over 70 years old). This disease remains a severe pathology due in particular to its vascular, ophthalmological, neurological, cardiac and aortic complications. In case of suspected CAG, management is a real therapeutic emergency. Indeed, only corticosteroid therapy started as early as possible can prevent the occurrence of these complications. The gold standard for the diagnosis of CAG has long been the temporal artery biopsy, but imaging is now considered as a 1st line diagnostic examination for the diagnosis of CAG according to the EULAR 2018 recommendations. Notably, temporal artery MRI has excellent sensitivity and specificity for diagnosis. However, the high diagnostic performance of MRI has been achieved by performing 3D T1 black blood and fat saturation sequences in high resolution (\<0.7mm), which are not accessible in all centers in France and worldwide. The realization of identical sequences with a lower resolution could allow a greater generalization of these sequences and improve the diagnostic management of GCA patients, including in non-expert centers. The objective of our study is to investigate the diagnostic performance of several 3D T1 black blood and fat saturation sequences for the diagnosis of GCA.

Eligibility

Min Age: 18 Years

Inclusion Criteria7

Patient over 18 years of age
Referred for imaging for an injected MRI for suspected GCA
Suspicion of GCA based on the presence of three major criteria or two major and one minor criteria defined as follows:
Major criteria: Age \> 50 years; Headache of recent onset; Claudication of the jaw, tongue or swallowing disorders; Visual problems (blindness, diplopia, blurred vision - including visual accidents occurring during the first week of treatment); Sedimentation rate at 1st hour \> 50 and/or CRP \> 8mg/l
Minor criteria: Hypersensitivity or induration of the scalp or presence of nodules remote from the temporal artery; Temporal artery abnormalities on palpation; Facial pain or feeling of facial edema; General signs (fever \>38°C, weight loss \>10%, anorexia, malaise, asthenia).
Cconsent to participate in the study
Affiliated or beneficiary of a social security plan

Exclusion Criteria7

Newly diagnosed malignant disease (diagnosed less than one year prior to inclusion)
Active infectious disease
Autoimmune disease (especially but not limited to: Wegener's disease, Takayasu vasculitis, ANCA vasculitis, rheumatoid arthritis, lupus erythematosus, periarteritis nodosa).
Systemic corticosteroid therapy for more than 10 days at high dose (\>0.5mg/kg/d of prednisone)
Contraindication to MRI
Patient benefiting from a legal protection measure
Pregnant or breastfeeding woman

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.